St. Baldrick’s supporters, this is a day to celebrate! You have helped make history. Today, the FDA approved the first gene therapy available in the United States. Called Kymriah, it’s an entirely new way of treating cancer and it’s saving lives.
This “living drug” is for patients with a type of acute lymphoblastic leukemia (ALL), a cancer of the blood and bone marrow and the most common form of childhood cancer. Scientists genetically modify a patient’s own immune cells in the lab, then infuse these new cells back into the patient’s body. These modified cells – called CAR T cells or chimeric antigen receptor T cells – then prompt the child’s own immune system to attack and kill leukemia cells.
As one of the most exciting projects supported by St. Baldrick’s – the SU2C-St. Baldrick’s Pediatric Cancer Dream Team – nears the end of its funding, a group of expert reviewers met at Stanford University on July 14th to evaluate its impact to date. To say they were impressed would be an understatement.
Members of the Dream Team gather at a meeting in July to discuss the impact of their research efforts.
The day began with a report from Dr. Stephan Grupp, director of the Cancer Immunotherapy Program at Children’s Hospital of Philadelphia.
He had flown to the Dream Team meeting straight from the Maryland headquarters of the Food and Drug Administration (FDA), where hundreds had packed a hearing room the day before. An FDA advisory panel was considering what could soon be the first gene therapy to be marketed in the United States, pioneered by Dr. Grupp and his colleagues.
When the school bell rang for summer break, what did you do? Swim like a fish? Swing as high as the stars? Swoon over your summer love? Press pause on reliving those childhood glory days for a second, because we’ve got great news. Together, we are helping kids with cancer get back to being kids — all that summer fun included. Say hello to our 2017 Summer Grants!
Dr. Hilary Marusak received a St. Baldrick’s Supportive Care Research grant for her work studying whether a martial arts therapy that focuses on meditation and breathing techniques can reduce pain — and pain’s negative long-term impact — in kids with cancer and survivors.
Today, St. Baldrick’s is proud to announce our latest round of grants — our 2017 Summer Grants, totaling $23.5 million.
Last year, St. Baldrick’s teamed up with the National Brain Tumor Society (NBTS) to defeat pediatric brain cancer. And now, just in time for Brain Cancer Awareness month, the NBTS has some promising news.
Last September, during the annual commemoration of Childhood Cancer Awareness Month in the United States, National Brain Tumor Society teamed-up with the St. Baldrick’s Foundation to introduce a new initiative to boldly reimagine the way the deadliest of pediatric cancers are researched.
In hindsight, the launch for our Defeat Pediatric Brain Tumors Research Collaborative couldn’t have come soon enough.
Meet the newest winner of the Robert J. Arceci Innovation Award — Dr. Kim Stegmaier. Dr. Stegmaier always loved kids but never thought she’d work in a lab trying to help them. Never say never! Read on to learn more about Dr. Stegmaier, her pioneering work in kids’ cancer research and her memorable meeting with Dr. Arceci himself.
Dr. Kim Stegmaier is the Vice Chair of Pediatric Oncology Research at the Dana-Farber Cancer Institute and the co-director of the Pediatric Hematologic Malignancy Program at Boston Children’s Hospital and Dana-Farber. Photo by Samuel Ogden
In her fifth year of medical school, Dr. Kimberly Stegmaier fell in love.
No, she didn’t fall in love with a cute fellow student. And no, she wasn’t pining for a lab tech either.
It’s National Volunteer Week and at St. Baldrick’s we have a lot of reasons to celebrate — like nearly 45,000 reasons! (Yep, that’s how many people volunteered for St. Baldrick’s this year and we love them ALL!) From team captains to barbers to shavees to VEOs and beyond— St. Baldrick’s is volunteer-powered and proud. Why do our incredible volunteers do what they do? Find out from three of our heroes!
Today’s the day! (Drumroll please!) It’s time to announce some exciting news — St. Baldrick’s very first grants of the year are here, with more to come. Read on to learn about our 2017 Summer Fellow grants, how these grants build a brighter future for children’s cancer research and how YOU made this support possible.
Our 2017 Summer Fellow grants are here!
This year, 21 institutions will receive $5,000, which will support medical school or college students working on a childhood cancer research project.
The Administration’s FY18 Budget proposes a $5.8 billion cut to the National Institutes of Health — a move that St. Baldrick’s researcher Dr. Jeffrey Lipton finds concerning for the future of childhood cancer research. Read on for more about the proposed budget, Dr. Lipton’s fears and what YOU can do about it.
As a physician scientist who has treated children with cancer for decades, I am deeply concerned about the President’s proposed federal budget for the coming year.
I know this budget will be carefully reviewed by many, and that Congress holds the purse strings. That’s why I’m counting on our champions in the House and Senate to stand up for our children.
This week the St. Baldrick’s Foundation calls to your attention two urgent challenges.
First, the new federal budget proposal calls for a cut of nearly 20% for the National Institutes of Health (NIH), the largest funding source for childhood cancer research.
Neuroblastoma. Immunotherapy. Malignant.
These are words no child should know.
Unfortunately, kids with cancer know them all too well.
« Newer PostsOlder Posts »